Andrea Bartolo, Augusto Di Castelnuovo, Andrea Wlderk, Marcello Bartolo, Salvatore Mangiafico, Marco Ciavarro, Giovanni Grillea
Diagnostic and Therapeutic Neuroradiology Unit, IRCCS Istituto Neurologico Mediterraneo NEUROMED, Pozzilli, Italy.
Research Unit of Epidemiology and Prevention, IRCCS Istituto Neurologico Mediterraneo NEUROMED, Pozzilli, Italy.
Neuroradiol J. 2025 Aug 12:19714009251362819. doi: 10.1177/19714009251362819.
ObjectiveTo evaluate the efficacy and safety of the Silk Vista flow diverter stent in treating recurrent cerebral bifurcation aneurysms, highlighting angiographic and clinical outcomes in a monocentric case series.MethodsA retrospective analysis of 12 patients (7 male, five female) with recurrent bifurcation aneurysms treated exclusively with the Silk Vista flow diverter was conducted. Aneurysms were located in the anterior communicating artery (75%), middle cerebral artery (17%), and basilar artery (8%). All patients received dual antiplatelet therapy for ten days pre-procedure and 6 months post-procedure, followed by aspirin monotherapy. The O'Kelly-Marotta (OKM) scale was used to assess aneurysm filling, where Grade D indicates complete occlusion. Clinical outcomes were measured using the modified Rankin Scale (mRS), with scores of 0-1 reflecting no or minimal disability.ResultsAt the end of the procedure, 75% ( = 9) of patients exhibited stagnant contrast filling within the aneurysm sac (OKM Grade C) during the venous phase. Periprocedural thromboembolic complications occurred in 17% ( = 2) of cases, without clinical sequelae. No post-hospital complications were observed, and all patients maintained mRS scores of 0-1 at discharge. At 1-year follow-up, complete aneurysm exclusion (OKM Grade D) was achieved in 83% ( = 10), while minimal neck perfusion (OKM Grade C) persisted in 17% ( = 2). No new neurological deficits or deterioration occurred.ConclusionDespite the small sample size and single-center design, the Silk Vista flow diverter demonstrated favorable angiographic and clinical outcomes, supporting its role as a viable and safe option in this complex patient population.
目的
评估Silk Vista血流导向支架治疗复发性大脑分叉动脉瘤的有效性和安全性,重点关注单中心病例系列中的血管造影和临床结果。
方法
对12例(7例男性,5例女性)仅采用Silk Vista血流导向支架治疗的复发性分叉动脉瘤患者进行回顾性分析。动脉瘤位于前交通动脉(75%)、大脑中动脉(17%)和基底动脉(8%)。所有患者在术前10天和术后6个月接受双联抗血小板治疗,随后采用阿司匹林单药治疗。使用奥凯利-马罗塔(OKM)量表评估动脉瘤充盈情况,其中D级表示完全闭塞。使用改良Rankin量表(mRS)测量临床结果,得分0-1表示无残疾或轻度残疾。
结果
在手术结束时,75%(n = 9)的患者在静脉期动脉瘤腔内出现造影剂滞留(OKM C级)。围手术期血栓栓塞并发症发生率为17%(n = 2),无临床后遗症。未观察到出院后并发症,所有患者出院时mRS评分均维持在0-1分。在1年随访时,83%(n = 10)的患者实现了动脉瘤完全闭塞(OKM D级),17%(n = 2)的患者仍有最小的颈部灌注(OKM C级)。未出现新的神经功能缺损或病情恶化。
结论
尽管样本量小且为单中心设计,但Silk Vista血流导向支架显示出良好的血管造影和临床结果,支持其在这一复杂患者群体中作为一种可行且安全的选择的作用。